It lost two big pharmacy benefit managers, Prime Therapeutics and Tricare, to Walgreens (NASDAQ: WBA) in the second half of the year. But consider earnings were artificially lowered due to extinguishing debt early and extra expenses for noncancelable lease obligations it had to pay as it closed some stores to streamline last year. Realistically, CVS should be able to manage long-term organic net income growth of around 5% to 7% per year thanks to aging baby boomers' need for prescriptions combined with inflation and margin improvements.